← All trials
NCT05879107
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2023
- Primary completion
- Dec 11, 2023
- Completion date
- May 28, 2024
- First posted
- May 30, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 1113
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.